Etodolac NOBEL retard 600 mg
Etodolac NOBEL retard 600 mg is a medicine authorised by Swissmedic under authorisation number 68635. The authorisation holder is NOBEL Pharma Schweiz AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 18 January 2023 and the authorisation is limited until 17 January 2028. ATC code M01AB08 places the medicine in the group Anti-inflammatory and antirheumatic products.
| Authorisation number | 68635 |
|---|---|
| Name | Etodolac NOBEL retard 600 mg |
| Full name | Etodolac NOBEL retard 600 mg, Filmtabletten |
| Authorisation holder | NOBEL Pharma Schweiz AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | M01AB08 |
| First authorisation | 18 January 2023 |
| Authorisation validity | 17 January 2028 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Etodolac NOBEL retard 600 mg, Filmtabletten | B | 18 January 2023 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 30 | Tablette(n) | M01AB08 | 07.10.1. | B |
| 2 | 100 | Tablette(n) | M01AB08 | 07.10.1. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Etodolac NOBEL retard 600 mg authorised in Switzerland?
Yes. Etodolac NOBEL retard 600 mg is authorised by Swissmedic under authorisation number 68635, data as of 01 September 2026. The authorisation is limited until 17 January 2028.
Which dispensing category does Etodolac NOBEL retard 600 mg have?
Etodolac NOBEL retard 600 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Etodolac NOBEL retard 600 mg?
The authorisation holder is NOBEL Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.